Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 520 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Drug Resistance Clear all

Conditions: Brain Tumor Adult
Interventions: DRI cell therapy; Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Trachoma
Interventions: Azithromycin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 320,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Eye exam, Oral exam, CT scan, Neuropsychological testing, Electrocardiogram, Echocardiogram; Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Methicillin-Resistant Staphylococcus Aureus
Interventions: Not listed
Lead sponsor: West Virginia University; Other
Eligibility: Not listed
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Epilepsy
Interventions: Brain Interchange System; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 3 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Rochester, Minnesota • Houston, Texas

Conditions: Ovarian Carcinoma
Interventions: Sacituzumab govitecan; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Malaria
Interventions: AQ-13, Chloroquine (CQ) Treatment; Drug
Lead sponsor: Tulane University Health Sciences Center; Other
Eligibility: 21 Years to 45 Years
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Focal Epilepsy, Intractable Epilepsy, Epileptic Encephalopathy, Lennox Gastaut Syndrome, Symptomatic Epilepsy, Generalized Epilepsy
Interventions: Reveal LINQ ICM System; Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 50 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Epilepsy, Focal Seizures, Partial Seizures
Interventions: Natalizumab, Placebo; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 26 more

Conditions: Refractory Epilepsy, Arrhythmia, Sudden Death
Interventions: Medtronic REVEAL; Device
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 16 Years to 49 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Insulin Resistance, Metabolic Syndrome X, Schizophrenia and Disorders With Psychotic Features, Mood Disorders, Psychotic Disorders
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 30 Years to 66 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Atherosclerotic Cardiovascular Disease, Metabolic Syndrome
Interventions: Health Education, Transcendental Meditation; Behavioral
Lead sponsor: Robert Schneider, MD; Other
Eligibility: 55 Years and older · Female only
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia

Conditions: Epilepsy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 4 Years and older
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bacterial Pneumonia
Interventions: Ceftaroline fosamil for Injection, IV Ceftriaxone, Placebo, Clarithromycin; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 606 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: Los Angeles, California • Pasadena, California • Sacramento, California + 9 more

Conditions: Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer
Interventions: IMGN151; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 32
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 27 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions: tisotumab vedotin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: San Jose, California • Fort Collins, Colorado • Miami, Florida + 14 more

Conditions: Epilepsy Intractable
Interventions: Stereoelectroencephalography (SEEG); Other
Lead sponsor: Duke University; Other
Eligibility: 15 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Gainesville, Florida • Chicago, Illinois • Durham, North Carolina + 1 more

Conditions: Pneumocystis Infection, Infection, Pneumonia, Pneumocystis, Lung Disease, Fungal, Mycoses
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 99 Years
Enrollment: 1,015 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action, Neurotransmitter Agents, Excitatory Amino Acid Agents, Physiological Effects of Drugs, Depressive Disorder, Major, Depressive Disorder, Depression, Mental Disorders, Mood Disorders, Behavioral Symptoms
Interventions: (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg), Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Refractory Epilepsy
Interventions: Traditional Treatment (Group T), Ketamine Infusion (Group K); Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Refractory Epilepsy
Interventions: Neurostimulation; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Not listed
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Treatment Resistant Depression
Interventions: Ketamine Infusion plus RO DBT; Combination Product
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HIV Infections
Interventions: Indinavir sulfate, Efavirenz, Levocarnitine, Adefovir dipivoxil; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 11
States / cities: Los Angeles, California • New Haven, Connecticut • Wilmington, Delaware + 8 more

Conditions: Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions: Conjunctival and nasopharyngeal swabs; Other
Lead sponsor: Prism Vision Group; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Edison, New Jersey

Search by objective public record fields.

Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma

Kebele Elimination of Trachoma for Ocular Health

Effect of Tenofovir DF on Bone Metabolism in Children

Comparison of Bacterial Contamination Rates Between Isolation and Non-isolation Rooms

Acute Stimulation and Modulation of Stereotyped High-Frequency Oscillations

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine

Long-term Cardiac Monitoring in Epilepsy

Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

Cardiac Rhythm Abnormalities in Patients With Refractory Epilepsy at High Risk for Sudden Death

Side Effects of Antipsychotic Medications

Multicenter Trial of Meditation and Health Education for Cardiometabolic Disease in Black Women

Study of Specimens Obtained During Epilepsy Surgery

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

5-SENSE Score Validation Study

New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus

Optimal Stimulation Parameters to Disrupt Epileptiform Activity

KET-RO Plus RO DBT for Treatment Resistant Depression

Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir

Resistance to Antibiotics in Patients Receiving Eye Injections